Sales Nexus CRM

MEDICLIN Reports Solid First Half of 2026 with Revenue and EBIT Growth

By Advos
MEDICLIN's first-half 2026 results show consolidated revenues up 5% to EUR 386.4 million and EBIT rising to EUR 26.6 million, driven by stability in core businesses and efficient cost management.
MEDICLIN Reports Solid First Half of 2026 with Revenue and EBIT Growth

MEDICLIN Aktiengesellschaft (Ticker: MED; WKN 659 510) reported consolidated group revenues of EUR 386.4 million for the first half of 2026, an increase of 5.0% from EUR 368.1 million in the same period last year. Group EBIT improved by EUR 4.3 million to EUR 26.6 million, compared to EUR 22.4 million in the prior year. The company treated 54,708 patients in the first half, up from 53,183 a year earlier.

CFO Tino Fritz attributed the performance to consistent momentum from the first quarter, stating, "Stability in our core business areas, efficient cost management and targeted investments have helped us to achieve our earnings targets for the second quarter." He emphasized the company's commitment to maintaining this momentum for long-term growth.

In the Post-Acute segment, revenues rose 4.6% to EUR 263.0 million, driven by a slight decrease in the cost of materials ratio to 19.0% and a reduction in absolute cost of materials. However, staff costs increased by 7.2% to EUR 145.2 million, pushing the staff costs ratio to 55.2%. Segment EBIT improved to EUR 25.6 million from EUR 23.3 million.

The Acute Care segment saw revenues grow to EUR 111.2 million from EUR 104.6 million, but cost of materials increased by 12.2% to EUR 34.6 million, raising the cost of materials ratio to 31.1%. Staff costs rose 6.3% to EUR 68.6 million, with the staff cost ratio stable at 61.7%. Segment EBIT remained negative at EUR -1.1 million, unchanged from the prior year.

Revenue in the Care segment edged up to EUR 12.3 million, and segment EBIT turned positive at EUR 0.2 million, compared to a loss of EUR 0.2 million last year. The Service segment reported other income of EUR 69.2 million, slightly up from EUR 68.5 million, and EBIT improved to EUR 1.9 million from EUR 0.5 million.

For the full financial year, management expects consolidated group revenue growth of 3.5% to 6.5% and group EBIT in the range of EUR 57.0 million to EUR 72.0 million. The interim report as of June 30, 2026, is available on the company's website at www.mediclin.de in German and English.

Advos

Advos

@advos